Acute lung injury and acute respiratory distress syndrome: Mechanisms and potential new therapies

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 1, 2004, Pages 123-128

  Prudhomme, Julie B ^a   Ware, Lorraine B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; KERATINOCYTE GROWTH FACTOR; KETOCONAZOLE; MONOCLONAL ANTIBODY; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E1; RECOMBINANT PROTEIN; SALBUTAMOL; SOMATOMEDIN C; SURFACTANT; TETRACYCLINE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD CLOTTING; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; FIBRINOLYSIS; HUMAN; LUNG FLUID; NEUTROPHIL; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 23744444850     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.08.009     Document Type: Review

References (28)

1. The Acute Respiratory Distress Syndrome Network, (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 342, 1301-1308
2. Bernard, G.R. et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709
3. Ware, L.B. and Matthay, M.A. (2000) The acute respiratory distress syndrome. N. Engl. J. Med. 342, 1334-1349
4. Welty-Wolf, K.E. et al. (2001) Tissue factor in experimental acute lung injury. Semin. Hematol. 38, 35-38
5. Prabhakaran, P. et al. (2003) Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L20-L28
6. Carraway, M.S. et al. (2003) Blockade of tissue factor, treatment for organ injury in established sepsis. Am. J. Respir. Crit. Care Med. 167, 1200-1209
7. Idell, S. (2003) Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit. Care Med. 31, S213-S220
8. Barazzone, C. et al. (1996) Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J. Clin. Invest. 98, 2666-2673
9. Moraes, T.J. et al. (2003) Proteases in lung injury. Crit. Care Med. 31, S189-S194
10. Delclaux, C. et al. (1997) Gelatinases in epithelial lining fluid of patients with adult respiratory distress syndrome. Am. J. Physiol. 272, L442-L451
11. Steinberg, J. et al. (2003) Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J. Surg. Res. 111, 185-195
12. 2- agonists and the acute respiratory distress syndrome. Crit. Care 8, 25-32
13. Ware, L.B. et al. (2001) Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 163, 1376-1383
14. 2-adrenergic receptor signaling. Circ. Res. (published online, accessed at http://www.circresaha.org)
15. 2-adrenergic agonists achieve therapeutic levels in the pulmonary edema fluid of ventilated patients with acute respiratory failure. Intensive Care Med. 28, 705-711
16. Ware, L.B. and Matthay, M.A. (2002) Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L924-L940
17. Ulich, T.R. et al. (1994) Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J. Clin. Invest. 93, 1298-1306
18. Atabai, K. et al. (2002) Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms. Am. J. Physiol. Lung Cell. Mol. Physiol. 283, L163-L169
19. Krein, P.M. et al. (2003) Localization of insulin-like growth factor-1 in lung tissues of patients with fibroproliferative acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 167, 83-90
20. Verbecke, K. et al. (2004) Inhibition of plasminogen activator inhibitor-1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs. J. Thromb. Haemost. 2, 298-305
21. Bernard, G.R. et al. (1987) High-dose corticosteroids in patients with adult respiratory distress syndrome. N. Engl. J. Med. 317, 1565-1570
22. Luce, J.M. et al. (1988) Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am. Rev. Respir. Dis. 136, 62-68
23. Abraham, E. et al. (1999) Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. Crit. Care Med. 27, 1478-1485
24. Bone, R.C. et al. (1989) Randomized, double-blinded, multicenter study of prostaglandin E1 in patients with adult respiratory distress syndrome. Chest 96, 114-119
25. Anzuito, A. et al. (1996) Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N. Engl. J. Med. 334, 1417-1421
26. Dellinger, R.P. et al. (1998) Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit. Care Med. 26, 15-23
27. Payen, D. et al. (1999) Results of the French prospective multicentric randomized, double-blind, placebo-controlled trial on inhaled nitric oxide in ARDS. Intensive Care Med. 25 (Suppl.), S166
28. NIH ARDS Network, (2000) Ketoconazole does not reduce mortality in patients with acute respiratory distress syndrome. J. Am. Med. Assoc. 283, 1995-2002